Jun Luo

18.7k citations

146 papers · 9.4k indexed · 4 hit papers · h-index 50

Impact in

Cancer Research top 0.2%
- Cancer, Lipids, and Metabolism
- Cancer-related molecular mechanisms research
Pulmonary and Respiratory Medicine top 0.2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment

Papers in

Pulmonary and Respiratory Medicine 97
- Prostate Cancer Treatment and Research 94
- Prostate Cancer Diagnosis and Treatment 21
Cancer Research 38
- Cancer, Lipids, and Metabolism 15
- Cancer Genomics and Diagnostics 14

Co-authors: William B. Isaacs Emmanuel S. Antonarakis Changxue Lu Rong Hu Angelo M. De Marzo Thomas A. Dunn Charles M. Ewing Samuel R. Denmeade
Journals: Journal of Clinical Oncology (18 papers)The Prostate (16 papers)Cancer Research (12 papers)Prostate Cancer and Prostatic Diseases (6 papers)European Urology (5 papers)
Partner nations: United States China United Kingdom

In The Last Decade

Jun Luo

141 papers receiving 9.3k citations

Hit Papers

align trajectories log scale

Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide 2017 · 340 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2017 Journal of Clinical Oncology
2015 JAMA Oncology
2012 Cancer Research
2008 Cancer Research

Peers

Countries citing papers authored by Jun Luo

Since Specialization

Citations

This map shows the geographic impact of Jun Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Luo more than expected).

Fields of papers citing papers by Jun Luo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Luo. The network helps show where Jun Luo may publish in the future.

Co-authors

The 25 scholars most cited alongside Jun Luo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jun Luo Line = papers co-authored together Jun Luo links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant Prostate Cancer and Prostatic Diseases ·Mayuko Kanayama, Émeline Colomba, Yusra F. Shao, Sarah M. Nielsen, Edward D. Esplin, Changxue Lu, William B. Isaacs, John C. Henegan, Elisabeth I. Heath, Jun Luo, Régine Marlin, Emmanuel S. Antonarakis	2025	0
2	Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated Cancers Cancers ·Catherine H. Marshall, Ali T. Arafa, Ellen Jaeger, Stamatina Fragkogianni, Anne Sonnenschein, Elizabeth Mauer, Lukasz P. Gondek, Calvin Chao, Jun Luo, Emmanuel S. Antonarakis	2025	0
3	Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153). Journal of Clinical Oncology ·Christos E. Kyriakopoulos, Yu‐Hui Chen, Robert Jeraj, Fenghai Duan, Jun Luo, Emmanuel S. Antonarakis, Abhishek Tripathi, David Kosoff, Rohan Garje, Russell K. Pachynski, Rahul Atul Parikh, Andrea Harzstark, Nabil Adra, Benjamin L. Maughan, Yousef Zakharia, Paul G. Corn, Glenn Liu, Michael A. Carducci	2024	2
4	The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated with Abiraterone or Enzalutamide Clinical Cancer Research ·Susan Halabi, Siyuan Guo, Joseph J. Park, David M. Nanus, Daniel J. George, Emmanuel S. Antonarakis, Daniel C. Danila, Russell Z. Szmulewitz, Donald P. McDonnell, John D. Norris, Changxue Lu, Jun Luo, Andrew J. Armstrong	2024	8
5	Association of PARP inhibitor treatment on the prevalence and progression of clonal hematopoiesis in patients with advanced prostate cancer The Prostate ·Catherine H. Marshall, Lukasz P. Gondek, В. Даниэльс, Changxue Lu, Sergiu Paşca, Jiajun Xie, Mark C. Markowski, Channing J. Paller, Laura A. Sena, Samuel R. Denmeade, Jun Luo, Emmanuel S. Antonarakis	2024	10
6	Clinical and Functional Analyses of an African-ancestry Gain-of-function HOXB13 Variant Implicated in Aggressive Prostate Cancer European Urology Oncology ·Mayuko Kanayama, Yidong Chen, Daniel Rabizadeh, Lauren Vera, Changxue Lu, Sarah M. Nielsen, Emily M. Russell, Edward D. Esplin, Hao Wang, William B. Isaacs, Emmanuel S. Antonarakis, Jun Luo	2023	5
7	Discovery of a Small-Molecule Inhibitor Targeting the Androgen Receptor N-Terminal Domain for Castration-Resistant Prostate Cancer Molecular Cancer Therapeutics ·Qianhui Yi, Weiguo Liu, Jung Hwa Seo, Jie Su, Moulay A. Alaoui‐Jamali, Jun Luo, Rongtuan Lin, Jian Wu	2023	11
8	The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer Nature Communications ·Keliang Wang, Jie Luo, Shuyuan Yeh, Bosen You, Jialin Meng, Philip Chang, Yuanjie Niu, Gonghui Li, Changxue Lu, Yezi Zhu, Emmanuel S. Antonarakis, Jun Luo, Chi‐Ping Huang, Wanhai Xu, Chawnshang Chang	2020	52
9	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization Prostate Cancer and Prostatic Diseases ·Jillian N. Eskra, Daniel Rabizadeh, Leslie A. Mangold, Elizabeth Fabian, W. Nathaniel Brennen, David B. Yeater, Kenneth J. Pienta, Alan W. Partin, William B. Isaacs, Christian P. Pavlovich, Jun Luo	2020	2
10	SF3B2-Mediated RNA Splicing Drives Human Prostate Cancer Progression Cancer Research ·Norihiko Kawamura, Keisuke Nimura, Kotaro Saga, Airi Ishibashi, Koji Kitamura, Hiromichi Nagano, Yusuke Yoshikawa, Kyoso Ishida, Norio Nonomura, Mitsuhiro Arisawa, Jun Luo, Yasufumi Kaneda	2019	55
11	A pilot study of prostate‐specific membrane antigen (PSMA) dynamics in men undergoing treatment for advanced prostate cancer The Prostate ·Channing J. Paller, Danilo Piana, James R. Eshleman, Stacy Riel, Samuel R. Denmeade, Pedro Isaacsson Velho, Steven P. Rowe, Martin G. Pomper, Emmanuel S. Antonarakis, Jun Luo, Mario A. Eisenberger	2019	18
12	Analytic Validation of RNA In Situ Hybridization (RISH) for AR and AR-V7 Expression in Human Prostate Cancer Clinical Cancer Research ·Liana B. Guedes, Carlos L. Morais, Fawaz Almutairi, Michael C. Haffner, Qizhi Zheng, John T. Isaacs, Emmanuel S. Antonarakis, Changxue Lu, Harrison Tsai, Jun Luo, Angelo M. De Marzo, Tamara L. Lotan	2016	25
13	A Paracrine Role for IL6 in Prostate Cancer Patients: Lack of Production by Primary or Metastatic Tumor Cells Cancer Immunology Research ·Shu-Han Yu, Qizhi Zheng, David Esopi, Anne Macgregor-Das, Jun Luo, Emmanuel S. Antonarakis, Charles G. Drake, Robert L. Vessella, Colm Morrissey, Angelo M. De Marzo, Karen S. Sfanos	2015	34
14	Stress-Response Protein RBM3 Attenuates the Stem-like Properties of Prostate Cancer Cells by Interfering with CD44 Variant Splicing Cancer Research ·Yu Zeng, Dana Wodzenski, Dong Gao, Takumi Shiraishi, Naoki Terada, Youqiang Li, Donald J. Vander Griend, Jun Luo, Chuize Kong, Robert H. Getzenberg, Prakash Kulkarni	2013	49
15	Tasquinimod Is an Allosteric Modulator of HDAC4 Survival Signaling within the Compromised Cancer Microenvironment Cancer Research ·John T. Isaacs, Lizamma Antony, Susan L. Dalrymple, W. Nathaniel Brennen, Stephanie Gerber, Hans J. Hammers, Michel D. Wissing, Sushant K. Kachhap, Jun Luo, Li Xing, Per Björk, Anders Olsson, Anders Björk, Tomas Leanderson	2012	89
16	Distinct Transcriptional Programs Mediated by the Ligand-Dependent Full-Length Androgen Receptor and Its Splice Variants in Castration-Resistant Prostate Cancer Cancer Research ·Rong Hu, Changxue Lu, Elahe A. Mostaghel, Srinivasan Yegnasubramanian, Meltem Ö. Gürel, Clare Tannahill, Joanne Edwards, William B. Isaacs, Peter S. Nelson, Eric G. Bluemn, Stephen R. Plymate, Jun Luo Hit paper breakdown →	2012	451
17	Definition of a FoxA1 Cistrome That Is Crucial for G1 to S-Phase Cell-Cycle Transit in Castration-Resistant Prostate Cancer Cancer Research ·Chunpeng Zhang, Liguo Wang, Dayong Wu, Hongyan Chen, Zhong Chen, Jennifer M. Thomas‐Ahner, Debra L. Zynger, Jérôme Eeckhoute, Jindan Yu, Jun Luo, Myles Brown, Steven K. Clinton, Kenneth P. Nephew, Tim H.‐M. Huang, Wěi Li, Qianben Wang	2011	73
18	miR-21: An Androgen Receptor–Regulated MicroRNA that Promotes Hormone-Dependent and Hormone-Independent Prostate Cancer Growth Cancer Research ·Judit Ribas, Xiaohua Ni, Michael C. Haffner, Erik A. Wentzel, Amirali Salmasi, Wasim H. Chowdhury, Tarana A. Kudrolli, Srinivasan Yegnasubramanian, Jun Luo, Ron Rodriguez, Joshua T. Mendell, Shawn E. Lupold	2009	350
19	Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer Cancer Research ·Rong Hu, Thomas A. Dunn, Shuanzeng Wei, Sumit Isharwal, Robert W. Veltri, Elizabeth B. Humphreys, Misop Han, Alan W. Partin, Robert L. Vessella, William B. Isaacs, G. Steven Bova, Jun Luo Hit paper breakdown →	2008	830
20	Three dimensional culture of animal cells in a fibrous bed bioreactor / OhioLink ETD Center (Ohio Library and Information Network) ·Jun Luo	2002	3

About Jun Luo

Jun Luo is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Endocrinology, Diabetes and Metabolism, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 146 papers that have together received 9.4k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (94 papers), Hormonal and reproductive studies (25 papers), Prostate Cancer Diagnosis and Treatment (21 papers), Radiopharmaceutical Chemistry and Applications (20 papers), Cancer, Lipids, and Metabolism (15 papers), Cancer Genomics and Diagnostics (14 papers), Molecular Biology Techniques and Applications (14 papers) and PARP inhibition in cancer therapy (12 papers). The work is most often cited by research in Cancer Research (3.3k citations), Pulmonary and Respiratory Medicine (5.7k citations), Endocrinology, Diabetes and Metabolism (1.2k citations), Molecular Biology (4.6k citations) and Oncology (1.7k citations). Jun Luo has collaborated with scholars based in United States, China and United Kingdom. Frequent co-authors include William B. Isaacs, Emmanuel S. Antonarakis, Changxue Lu, Rong Hu, Angelo M. De Marzo, Thomas A. Dunn, Charles M. Ewing, Samuel R. Denmeade, Mario A. Eisenberger and Michael A. Carducci. Their work appears in journals such as Journal of Clinical Oncology, The Prostate, Cancer Research, Prostate Cancer and Prostatic Diseases and European Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact